Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug;26(8):1589-604.
doi: 10.1093/annonc/mdv257. Epub 2015 Jun 3.

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

S Gillessen  1 , A Omlin  2 , G Attard  3 , J S de Bono  3 , E Efstathiou  4 , K Fizazi  5 , S Halabi  6 , P S Nelson  7 , O Sartor  8 , M R Smith  9 , H R Soule  10 , H Akaza  11 , T M Beer  12 , H Beltran  13 , A M Chinnaiyan  14 , G Daugaard  15 , I D Davis  16 , M De Santis  17 , C G Drake  18 , R A Eeles  19 , S Fanti  20 , M E Gleave  21 , A Heidenreich  22 , M Hussain  23 , N D James  24 , F E Lecouvet  25 , C J Logothetis  26 , K Mastris  27 , S Nilsson  28 , W K Oh  29 , D Olmos  30 , A R Padhani  31 , C Parker  32 , M A Rubin  33 , J A Schalken  34 , H I Scher  35 , A Sella  36 , N D Shore  37 , E J Small  38 , C N Sternberg  39 , H Suzuki  40 , C J Sweeney  41 , I F Tannock  42 , B Tombal  43
Affiliations

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

S Gillessen et al. Ann Oncol. 2015 Aug.

Abstract

The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the available evidence for the ten most important areas of controversy in advanced prostate cancer (APC) management. The successful registration of several drugs for castration-resistant prostate cancer and the recent studies of chemo-hormonal therapy in men with castration-naïve prostate cancer have led to considerable uncertainty as to the best treatment choices, sequence of treatment options and appropriate patient selection. Management recommendations based on expert opinion, and not based on a critical review of the available evidence, are presented. The various recommendations carried differing degrees of support, as reflected in the wording of the article text and in the detailed voting results recorded in supplementary Material, available at Annals of Oncology online. Detailed decisions on treatment as always will involve consideration of disease extent and location, prior treatments, host factors, patient preferences as well as logistical and economic constraints. Inclusion of men with APC in clinical trials should be encouraged.

Keywords: advanced prostate cancer; castration-naïve prostate cancer; castration-resistant prostate cancer; consensus; therapeutics.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
How the Consensus Process works (modified Delphi process).
Figure 2.
Figure 2.
Conceptual framework: advanced prostate cancer.
Figure 3.
Figure 3.
(A, B and C) Summary of treatment options for advanced prostate cancer, March 2015.
Figure 3.
Figure 3.
(A, B and C) Summary of treatment options for advanced prostate cancer, March 2015.
Figure 4.
Figure 4.
(A and B) Osteoclast-targeted therapies for men with prostate cancer, March 2015.
See this image and copyright information in PMC

Comment in

References

    1. de Bono JS, Oudard S, Ozguroglu M et al. . Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147–1154. - PubMed
    1. Kantoff PW, Higano CS, Shore ND et al. . Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411–422. - PubMed
    1. de Bono JS, Logothetis CJ, Molina A et al. . Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995–2005. - PMC - PubMed
    1. Scher HI, Fizazi K, Saad F et al. . Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187–1197. - PubMed
    1. Parker C, Nilsson S, Heinrich D et al. . Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213–223. - PubMed

Publication types

MeSH terms